Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials

被引：0

作者：

Klaus F. Rabe

James D. Chalmers

Marc Miravitlles

Janwillem W. H. Kocks

Ioanna Tsiligianni

Alberto de la Hoz

Wenqiong Xue

Dave Singh

Gary T. Ferguson

Jadwiga Wedzicha

机构：

[1] LungenClinic Grosshansdorf,Tayside Respiratory Research Group

[2] Airway Research Center North,Pneumology Department

[3] German Center for Lung Research (DZL),Health Planning Unit, Department of Social Medicine, Faculty of Medicine

[4] Christian Albrechts University Kiel,Medicines Evaluation Unit (MEU)

[5] Airway Research Center North,Respiratory Division

[6] German Center for Lung Research (DZL),undefined

[7] University of Dundee,undefined

[8] Hospital Universitari Vall d’Hebron,undefined

[9] Vall d’Hebron Research Institute (VHIR),undefined

[10] CIBER de Enfermedades Respiratorias (CIBERES),undefined

[11] General Practitioners Research Institute,undefined

[12] Groningen Research Institute for Asthma and COPD (GRIAC),undefined

[13] University Medical Center Groningen,undefined

[14] University of Groningen,undefined

[15] Observational and Pragmatic Research Institute,undefined

[16] University of Crete,undefined

[17] Boehringer Ingelheim International GmbH,undefined

[18] Boehringer Ingelheim Pharmaceuticals,undefined

[19] Inc.,undefined

[20] University of Manchester,undefined

[21] Manchester University NHS Foundation Trust,undefined

[22] Pulmonary Research Institute of Southeast Michigan,undefined

[23] National Heart and Lung Institute,undefined

[24] Imperial College London,undefined

来源：

Advances in Therapy | 2021年 / 38卷

关键词：

Chronic obstructive pulmonary disease; Exacerbations; Health status; Lung function; Olodaterol; Tiotropium;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

COPD is a complicated disease that deteriorates over time. Worsening of COPD is associated with the lungs working less effectively, a fall in quality of life and a rise in sudden flare-ups of the disease. In this study, we looked at lung function, quality of life and flare-ups together using a measure called “clinically important deterioration” (CID). We looked at 2055 people with COPD to compare the effects of taking two bronchodilators (tiotropium and olodaterol) against taking one bronchodilator (tiotropium alone). Bronchodilators are a type of inhaled medication that relax the muscles in the lungs and widen airways, making it easier to breathe. They have also been shown to reduce sudden flare-ups of COPD. Across a wide range of people with COPD, we found that treatment with tiotropium/olodaterol reduced the risk of a CID compared with tiotropium alone. This includes in those patients at an early stage of disease, who may benefit from finding the best treatment option for them as early as possible.

引用

页码：579 / 593

页数：14

共 107 条

[1] Cazzola M(2018)POINT: should LAMA/LABA combination therapy be used as initial maintenance treatment for COPD? Yes Chest 154 746-748
[2] Matera MG(2018)COUNTERPOINT: should LAMA/LABA combination therapy be used as initial maintenance treatment for COPD? No Chest 154 749-751
[3] Barrecheguren M(2020)Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline Am J Respir Crit Care Med 201 e56-e69
[4] Miravitlles M(2016)A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD Chest 149 1181-1196
[5] Nici L(2017)Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis Respir Med 129 189-198
[6] Mammen MJ(2016)Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis Thorax 71 15-25
[7] Charbek E(2018)Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis Cochrane Database Syst Rev 12 CD012620-4189
[8] Calzetta L(2020)Efficacy of tiotropium/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are naïve to LAMA, LABA and ICS: pooled analysis of four clinical trials Adv Ther 37 4175-3499
[9] Rogliani P(2020)Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of the TONADO Adv Ther 37 3485-108
[10] Matera MG(2012) and OTEMTO Prim Care Respir J 21 101-1703

← 1 2 3 4 5 6 7 8 9 10 →